Drug Approval | September 04, 2025
Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Subscribe To Our Newsletter & Stay Updated
